Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2018

  • ID: 4464786
  • Drug Pipelines
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CSL Ltd
  • GeNeuro SA
  • Octapharma AG
  • Pfizer Inc
  • Shire Plc
  • Teijin Pharma Ltd
  • MORE
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2018, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline landscape.

Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 4, 1 and 2 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CSL Ltd
  • GeNeuro SA
  • Octapharma AG
  • Pfizer Inc
  • Shire Plc
  • Teijin Pharma Ltd
  • MORE
Introduction

The Publisher's Report Coverage

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development

CSL Ltd

GeNeuro SA

Momenta Pharmaceuticals Inc

Octapharma AG

Pfizer Inc

Shire Plc

Teijin Pharma Ltd

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drug Profiles

GL-2045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNbAC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-254 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones

Featured News & Press Releases

Jan 26, 2018: CHMP Recommends Extension of Indications for Hizentra

Nov 09, 2017: Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Sep 14, 2017: CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults

Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

Jul 11, 2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders

Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed

Feb 14, 2017: FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition

Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy

Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen

Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy

May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by CSL Ltd, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Momenta Pharmaceuticals Inc, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Shire Plc, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Ltd, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H1 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CSL Ltd
  • GeNeuro SA
  • Momenta Pharmaceuticals Inc
  • Octapharma AG
  • Pfizer Inc
  • Shire Plc
  • Teijin Pharma Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll